- Home
- CKPT vs NNY Comparison
CKPT vs NNY Comparison
Compare CKPT & NNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- NNY
- Stock Information
- Founded
- CKPT 2014
- NNY 1987
- Country
- CKPT United States
- NNY United States
- Employees
- CKPT N/A
- NNY N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- NNY Investment Managers
- Sector
- CKPT Health Care
- NNY Finance
- Exchange
- CKPT Nasdaq
- NNY Nasdaq
- Market Cap
- CKPT 151.9M
- NNY 157.9M
- IPO Year
- CKPT 2017
- NNY N/A
- Fundamental
- Price
- CKPT $3.00
- NNY $8.15
- Analyst Decision
- CKPT Strong Buy
- NNY
- Analyst Count
- CKPT 2
- NNY 0
- Target Price
- CKPT $13.50
- NNY N/A
- AVG Volume (30 Days)
- CKPT 998.1K
- NNY 50.9K
- Earning Date
- CKPT 11-12-2024
- NNY 01-01-0001
- Dividend Yield
- CKPT N/A
- NNY 4.04%
- EPS Growth
- CKPT N/A
- NNY N/A
- EPS
- CKPT N/A
- NNY N/A
- Revenue
- CKPT $47,000.00
- NNY N/A
- Revenue This Year
- CKPT N/A
- NNY N/A
- Revenue Next Year
- CKPT $172,016.02
- NNY N/A
- P/E Ratio
- CKPT N/A
- NNY N/A
- Revenue Growth
- CKPT N/A
- NNY N/A
- 52 Week Low
- CKPT $1.38
- NNY $7.58
- 52 Week High
- CKPT $4.50
- NNY $8.87
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- NNY 50.87
- Support Level
- CKPT $3.07
- NNY $8.05
- Resistance Level
- CKPT $3.42
- NNY $8.13
- Average True Range (ATR)
- CKPT 0.21
- NNY 0.07
- MACD
- CKPT -0.03
- NNY 0.02
- Stochastic Oscillator
- CKPT 4.94
- NNY 63.33
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.